BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:UTAA17 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of UTAA17\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06279026-3352@assetmemo.bio
DTSTAMP:20261121T004539Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:UTAA17: Phase na readout est. (NCT06279026)
DESCRIPTION:UTAA17\, phase na\, Multiple Myeloma.\nStudy: UTAA17 Injection 
 in the Treatment of Relapsed/Refractory Multiple Myeloma\nEstimated primar
 y completion: 1 April 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/utaa17#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06279026
URL:https://assetmemo.bio/drug/utaa17#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
